Cell Type Matters
CAR-T for Oncology
CAR-T therapy is a form of anti-cancer therapy in which T cells are genetically modified to attack tumors, an approach that has revolutionized how cancer is treated. Currently, all commercially available CAR-T therapies are autologous, where the T cells are derived from each patient. Poseida believes that the future of CAR-T and our ability to offer new treatment options lies in allogeneic approaches, where the T cells are derived from healthy donors.
Our clinical and preclinical candidates are designed as off-the-shelf treatments for cancer. We modify healthy donor derived T cells using Cas-CLOVER gene editing to disrupt expression of T cell receptor beta and human leukocyte antigens (HLA). Specifically, T cell receptor beta gene deletion eliminates or reduces unwanted immune reactions, such as graft-versus-host-disease (GvHD). Beta-2 microglobulin gene deletion improves persistence by eliminating CAR-T rejection by the patient’s immune system via mismatched HLA proteins. The large cargo capacity of our piggyBac system allows us to develop allogeneic CAR-Ts able to target multiple antigens for greater tumor recognition capacity.
This allogeneic CAR-T candidate targeting B cell maturation antigen, or BCMA, is in development to treat relapsed/refractory multiple myeloma. This allogeneic program offers an improved VH-based binder which targets BCMA. This program is being developed in partnership with Roche and has shown early evidence of encouraging safety and efficacy.
This allogeneic dual CAR-T candidate targets both CD19 and CD20 antigens to treat B-cell malignancies. Dual targets address the limitations of single antigen loss and tumor variability. This program is being developed in partnership with Roche.
This allogeneic dual CAR-T candidate targets both BCMA and CD19 to treat relapsed/refractory multiple myeloma.
This allogeneic CAR-T candidate targets CD70 for the treatment of acute myeloid leukemia.
This allogeneic CAR-T candidate is in development for multiple solid tumor indications including breast, colorectal, lung, ovarian, pancreatic and renal carcinomas, as well as other cancers expressing a cancer-specific form of the Mucin 1 protein called MUC1-C.
This allogeneic CAR-T candidate targets prostate-specific membrane antigen, or PSMA, to treat prostate cancer. This allogeneic program offers improved VH-based binding technology targeting PSMA, which can potentially enhance anti-tumor efficacy.
We are developing several liver-directed gene therapies to address rare and life-threatening diseases that are often diagnosed in early infancy. Our initial focus utilizes piggyBac in combination with AAV and non-viral nanoparticles or fully non-viral nanoparticle delivery. Our long-term aim is to move to fully non-viral therapies.
Poseida welcomes partners and collaborators to help us translate our innovative technologies into cell and gene therapies with the capacity to cure. We know the challenges we face cannot be solved by one person – or even one organization. We strive to partner with leaders in their fields who share our commitment towards developing better and safer treatments for those with limited or no therapeutic options.
With Roche, our strategic collaboration focuses on allogeneic CAR-T therapies directed at hematologic malignancies. The partnership includes multiple existing Poseida programs along with the development of novel off-the-shelf cell therapies against targets in multiple myeloma, B-cell lymphoma, and other hematologic cancers.
Partner With Us
If you are interested in collaborating with Poseida to usher in a new class of innovative solutions for cell and gene therapies, please contact us. We are actively seeking potential collaborators in these areas:
- Allogeneic CAR-T or TCR-T therapies for solid tumors
- In vivo liver or other tissue-directed gene therapies
- Application of our technology in therapeutic areas beyond CAR-T and gene therapy
- Novel technologies that further enable our approaches to cell and gene therapy